Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$732.58
0.620.08%
À la fermeture: -
$730.75
-1.83-0.25%
Après les heures de négociation: 7:42 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Eli Lilly and Co a un objectif de cours consensus de $947.81, basé sur les évaluations des 28 analystes. Le plus élevé est de $1190 attribué par Citigroup le janvier 28, 2025, et le plus bas est de $610 attribué par Daiwa Capital le décembre 21, 2023. Les 3 dernières évaluations d'analystes ont été publiées par HSBC, Cantor Fitzgerald et Guggenheim le août 27, 2025, août 13, 2025 et août 13, 2025. Avec un objectif de cours moyen de $800 entre HSBC, Cantor Fitzgerald et Guggenheim, il y a une variation implicite de 9.48% upside pour Eli Lilly and Co à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
HSBC
Cantor Fitzgerald
Guggenheim
Deutsche Bank
JP Morgan
1calculé à partir des notes des analystes
Notes d'analystes pour Eli Lilly
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/27/2025 | -4.21% | HSBC | $675 → $700 | Upgrade | Reduce → Hold | |||
08/13/2025 | 12.9% | Cantor Fitzgerald | $975 → $825 | Maintains | Overweight | |||
08/13/2025 | 19.74% | Guggenheim | $942 → $875 | Maintains | Buy | |||
08/11/2025 | 23.16% | Deutsche Bank | $1010 → $900 | Maintains | Buy | |||
08/08/2025 | 50.53% | JP Morgan | $1100 → $1100 | Reiterates | Overweight → Overweight | |||
08/08/2025 | 22.48% | UBS | $1050 → $895 | Maintains | Buy | |||
07/11/2025 | 28.91% | Guggenheim | $936 → $942 | Maintains | Buy | |||
07/10/2025 | 55.32% | Morgan Stanley | $1133 → $1135 | Maintains | Overweight | |||
06/20/2025 | 28.09% | Guggenheim | $936 → $936 | Reiterates | Buy → Buy | |||
05/02/2025 | 43.69% | UBS | $1100 → $1050 | Maintains | Buy | |||
04/28/2025 | -4.21% | HSBC | $1150 → $700 | Downgrade | Buy → Reduce | |||
04/22/2025 | 33.42% | Cantor Fitzgerald | → $975 | Initiates | → Overweight | |||
04/14/2025 | 26.99% | Guggenheim | $973 → $928 | Maintains | Buy | |||
04/09/2025 | 53.81% | Morgan Stanley | $1146 → $1124 | Maintains | Overweight | |||
04/08/2025 | 21.52% | Goldman Sachs | $892 → $888 | Upgrade | Neutral → Buy | |||
03/05/2025 | 50.53% | Wells Fargo | $970 → $1100 | Maintains | Overweight | |||
02/03/2025 | 42.05% | Truist Securities | $1029 → $1038 | Maintains | Buy | |||
01/28/2025 | 32.74% | Wells Fargo | $1000 → $970 | Maintains | Overweight | |||
01/28/2025 | 62.85% | Citigroup | $1250 → $1190 | Maintains | Buy | |||
12/10/2024 | 36.43% | B of A Securities | → $997 | Reinstates | → Buy | |||
11/15/2024 | 36.85% | Wolfe Research | → $1000 | Initiates | → Outperform | |||
11/04/2024 | 38.9% | Deutsche Bank | $1025 → $1015 | Maintains | Buy | |||
10/31/2024 | 40.81% | Truist Securities | $1033 → $1029 | Maintains | Buy | |||
10/31/2024 | 33.42% | Barclays | $1025 → $975 | Maintains | Overweight | |||
10/31/2024 | 50.53% | B of A Securities | $1150 → $1100 | Maintains | Buy | |||
10/25/2024 | 71.06% | Citigroup | $1060 → $1250 | Maintains | Buy | |||
10/17/2024 | 50.53% | Bernstein | — | → $1100 | Initiates | → Outperform | ||
10/10/2024 | 41.36% | Truist Securities | $1000 → $1033 | Maintains | Buy | |||
10/03/2024 | 40.27% | Deutsche Bank | $1025 → $1025 | Reiterates | Buy → Buy | |||
09/16/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
09/13/2024 | 50.53% | JP Morgan | $1050 → $1100 | Maintains | Overweight | |||
09/13/2024 | 45.06% | Citigroup | → $1060 | Reinstates | Buy → Buy | |||
09/09/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/27/2024 | 51.35% | Morgan Stanley | $1106 → $1106 | Reiterates | Overweight → Overweight | |||
08/19/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
08/16/2024 | 40.95% | Guggenheim | $884 → $1030 | Maintains | Buy | |||
08/14/2024 | 43.69% | Berenberg | $1000 → $1050 | Maintains | Buy | |||
08/12/2024 | 40.27% | Deutsche Bank | $725 → $1025 | Upgrade | Hold → Buy | |||
08/09/2024 | 36.85% | Wells Fargo | $875 → $1000 | Maintains | Overweight | |||
08/09/2024 | 50.67% | BMO Capital | $1001 → $1101 | Maintains | Outperform | |||
08/09/2024 | 53.95% | B of A Securities | $1000 → $1125 | Maintains | Buy | |||
08/05/2024 | 20.97% | Guggenheim | $855 → $884 | Maintains | Buy | |||
08/05/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/24/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/15/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
07/11/2024 | 36.85% | Berenberg | $850 → $1000 | Maintains | Buy | |||
07/11/2024 | 36.85% | JP Morgan | $900 → $1000 | Maintains | Overweight | |||
07/10/2024 | 40.27% | Barclays | $913 → $1025 | Maintains | Overweight | |||
07/05/2024 | 39.99% | Morgan Stanley | $1023 → $1023 | Maintains | Overweight | |||
07/03/2024 | 36.98% | BMO Capital | $1001 → $1001 | Maintains | Outperform | |||
07/01/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/26/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/25/2024 | 36.85% | Truist Securities | $892 → $1000 | Reiterates | Buy → Buy | |||
06/24/2024 | 38.9% | Jefferies | $994 → $1015 | Maintains | Buy | |||
06/24/2024 | 36.85% | B of A Securities | $1000 → $1000 | Maintains | Buy | |||
06/24/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/20/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/17/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/12/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/11/2024 | 21.11% | Cantor Fitzgerald | $885 → $885 | Reiterates | Overweight → Overweight | |||
06/07/2024 | 30.96% | Jefferies | $925 → $957 | Maintains | Buy | |||
05/14/2024 | 14.95% | Argus Research | $770 → $840 | Maintains | Buy | |||
05/01/2024 | 36.98% | BMO Capital | $900 → $1001 | Maintains | Outperform | |||
05/01/2024 | 23.16% | JP Morgan | $850 → $900 | Maintains | Overweight | |||
05/01/2024 | 21.11% | Cantor Fitzgerald | $815 → $885 | Maintains | Overweight | |||
05/01/2024 | 22.07% | Truist Securities | $850 → $892 | Maintains | Buy | |||
04/30/2024 | 21.11% | Cantor Fitzgerald | $815 → $885 | Reiterates | Overweight → Overweight | |||
04/18/2024 | 11.53% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/15/2024 | 11.53% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/11/2024 | -1.06% | Goldman Sachs | $650 → $723 | Maintains | Neutral | |||
04/05/2024 | 11.53% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
04/03/2024 | — | Erste Group | — | Upgrade | Hold → Buy | |||
04/02/2024 | 22.48% | Citigroup | $675 → $895 | Maintains | Buy | |||
04/01/2024 | 11.53% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
03/22/2024 | 16.32% | Truist Securities | → $850 | Reiterates | Buy → Buy | |||
03/15/2024 | 16.32% | JP Morgan | $775 → $850 | Maintains | Overweight | |||
03/01/2024 | 36.85% | B of A Securities | $800 → $1000 | Maintains | Buy | |||
02/21/2024 | 12.21% | DZ Bank | → $820 | Downgrade | Buy → Hold | |||
02/20/2024 | 11.53% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/16/2024 | 30% | Morgan Stanley | $805 → $950 | Maintains | Overweight | |||
02/14/2024 | 11.53% | Cantor Fitzgerald | $815 → $815 | Reiterates | Overweight → Overweight | |||
02/07/2024 | 10.84% | Barclays | $680 → $810 | Maintains | Overweight | |||
02/07/2024 | 16.32% | Truist Securities | $650 → $850 | Maintains | Buy | |||
02/07/2024 | 10.16% | Morgan Stanley | $763 → $805 | Maintains | Overweight | |||
02/07/2024 | 12.9% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/07/2024 | 18.37% | BMO Capital | $710 → $865 | Maintains | Outperform | |||
02/06/2024 | 12.9% | Wells Fargo | $700 → $825 | Maintains | Overweight | |||
02/06/2024 | 11.53% | Cantor Fitzgerald | $630 → $815 | Maintains | Overweight | |||
02/05/2024 | -13.79% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
02/01/2024 | -13.79% | Cantor Fitzgerald | $630 → $630 | Reiterates | Overweight → Overweight | |||
01/24/2024 | -4.21% | Wells Fargo | $650 → $700 | Maintains | Overweight | |||
01/23/2024 | -13.79% | Cantor Fitzgerald | $630 → $630 | Reiterates | Overweight → Overweight | |||
01/23/2024 | -6.95% | Barclays | $630 → $680 | Maintains | Overweight | |||
12/21/2023 | -16.52% | Daiwa Capital | → $610 | Downgrade | Buy → Outperform | |||
11/29/2023 | -11.05% | Truist Securities | → $650 | Reiterates | Buy → Buy | |||
11/20/2023 | -13.79% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
11/17/2023 | -13.79% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
11/15/2023 | -13.79% | Cantor Fitzgerald | → $630 | Reiterates | Overweight → Overweight | |||
11/09/2023 | -26.79% | Deutsche Bank | → $535 | Initiates | → Hold |
FAQ
Quel est le cours indicatif de l'action Eli Lilly (LLY) ?
Le dernier objectif de prix pour Eli Lilly (NYSE:LLY) a été rapporté par HSBC le août 27, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $700.00 s'attendant à ce que LLY se fall dans les 12 prochains mois (un possible changement de -4.21% downside). 33 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Eli Lilly (LLY) ?
La dernière note d'analyste pour Eli Lilly (NYSE:LLY) a été fournie par HSBC, et Eli Lilly amélioré leur note hold.
Quand a eu lieu la dernière mise à niveau pour Eli Lilly (LLY) ?
La dernière amélioration pour Eli Lilly and Co a eu lieu le août 27, 2025 lorsque HSBC a augmenté leur objectif de prix à $700. HSBC avait précédemment a reduce pour Eli Lilly and Co.
Quand a eu lieu la dernière dégradation pour Eli Lilly (LLY) ?
La dernière réduction pour Eli Lilly and Co a eu lieu le avril 28, 2025 lorsque HSBC a changé leur objectif de prix de $1150 à $700 pour Eli Lilly and Co.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Eli Lilly (LLY) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Eli Lilly, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Eli Lilly a été déposée le août 27, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 27, 2026.
La note d'analyste pour Eli Lilly (LLY) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Eli Lilly (LLY) était un amélioré avec un objectif de prix de $675.00 à $700.00. Le prix actuel de Eli Lilly (LLY) est de $730.75, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.